StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –

Vaxart operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vaxart's operating income for the twelve months ending Jun 30, 2026 was $39.61M. For fiscal 2025 it was $18.07M. The highest annual figure on record is $18.07M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.07M–
FY2024Dec 31, 2024-$66.29M–
FY2023Dec 31, 2023-$83.35M–
FY2022Dec 31, 2022-$114.59M–
FY2021Dec 31, 2021-$72.75M–
FY2020Dec 31, 2020-$30.17M–
FY2019Dec 31, 2019-$15.79M–
FY2018Dec 31, 2018-$21.76M–
FY2016Jun 30, 2016-$25.20M–
FY2015Jun 30, 2015-$19.50M–
FY2014Jun 30, 2014-$11.50M–
FY2013Jun 30, 2013-$22.10M–
FY2012Jun 30, 2012-$22.90M–
FY2009Dec 26, 2009-$17.98M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$13.17M–
Q1 FY2026CQ1 2026Mar 31, 2026$5.17M–
Q4 FY2025CQ4 2025Dec 31, 2025$55.42M–
Q3 FY2025CQ3 2025Sep 30, 2025-$7.81M–
Q2 FY2025CQ2 2025Jun 30, 2025-$14.60M–
Q1 FY2025CQ1 2025Mar 31, 2025-$14.94M–
Q4 FY2024CQ4 2024Dec 31, 2024-$11.49M–
Q3 FY2024CQ3 2024Sep 30, 2024-$14.48M–
Q2 FY2024CQ2 2024Jun 30, 2024-$16.26M–
Q1 FY2024CQ1 2024Mar 31, 2024-$24.07M–
Q4 FY2023CQ4 2023Dec 31, 2023-$16.90M–
Q3 FY2023CQ3 2023Sep 30, 2023-$17.82M–
Q2 FY2023CQ2 2023Jun 30, 2023-$23.05M–
Q1 FY2023CQ1 2023Mar 31, 2023-$25.57M–
Q4 FY2022CQ4 2022Dec 31, 2022-$31.14M–
Q3 FY2022CQ3 2022Sep 30, 2022-$29.43M–
Q2 FY2022CQ2 2022Jun 30, 2022-$29.25M–
Q1 FY2022CQ1 2022Mar 31, 2022-$24.78M–
Q4 FY2021CQ4 2021Dec 31, 2021-$24.22M–
Q3 FY2021CQ3 2021Sep 30, 2021-$17.25M–
Q2 FY2021CQ2 2021Jun 30, 2021-$15.78M–
Q1 FY2021CQ1 2021Mar 31, 2021-$15.51M–
Q4 FY2020CQ4 2020Dec 31, 2020-$13.36M–
Q3 FY2020CQ3 2020Sep 30, 2020-$7.59M–
Q2 FY2020CQ2 2020Jun 30, 2020-$8.53M–
Q1 FY2020CQ1 2020Mar 31, 2020-$694.00K–
Q4 FY2019CQ4 2019Dec 31, 2019-$5.63M–
Q3 FY2019CQ3 2019Sep 30, 2019-$4.71M–
Q2 FY2019CQ2 2019Jun 30, 2019-$5.00M–
Q1 FY2019CQ1 2019Mar 31, 2019-$448.00K–
Q4 FY2018CQ4 2018Dec 31, 2018-$4.19M–
Q3 FY2018CQ3 2018Sep 30, 2018-$5.88M–
Q2 FY2018CQ2 2018Jun 30, 2018-$7.78M–
Q1 FY2018CQ1 2018Mar 31, 2018-$3.92M–
Q4 FY2016CQ2 2016Jun 30, 2016-$6.70M–
Q3 FY2016CQ1 2016Mar 31, 2016-$5.20M-572.7%
Q2 FY2016CQ4 2015Dec 31, 2015-$6.50M–
Q1 FY2016CQ3 2015Sep 30, 2015-$6.70M–
Q4 FY2015CQ2 2015Jun 30, 2015-$20.00M–
Q3 FY2015CQ1 2015Mar 31, 2015$1.10M–

More Vaxart figures

See a number that looks wrong?